Summit Therapeu ADR (SMMT)

$18.95 +0.29 (1.55%)
Market Cap 14.48B
Revenue (ttm) 0.00
Net Income (ttm) -1.08B
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 2,237,500
Avg Vol 3,661,772
Day's Range N/A - N/A
Shares Out 776.16M
Stochastic %K 53%
Beta -1.25
Analysts Strong Sell
Price Target $30.33

Company Profile

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical...

Industry: Biotechnology
Sector: Healthcare
Phone: 305 203 2034
Address:
601 Brickell Key Drive, Suite 1000, Miami, United States
LoveRetailFroth
LoveRetailFroth May. 13 at 1:19 PM
$REPL Good Morning ☕️ My 💎 s $AMLX $SMMT $RXRX $SANA
0 · Reply
Teluride
Teluride May. 12 at 11:21 PM
$SMMT
3 · Reply
TruthBroker2
TruthBroker2 May. 12 at 5:32 PM
$SMMT $PLSE They Know.
0 · Reply
TruthBroker2
TruthBroker2 May. 12 at 2:41 PM
$SMMT 18.88
0 · Reply
SmokeWagon
SmokeWagon May. 12 at 2:15 PM
$SMMT !!!
0 · Reply
LeisureSuitLarry
LeisureSuitLarry May. 12 at 1:51 PM
$SMMT
0 · Reply
LoveRetailFroth
LoveRetailFroth May. 12 at 1:48 PM
$REPL Good Morning 💎s $AMLX $SMMT $SANA $RXRX
0 · Reply
MauriceMauriceMaurice
MauriceMauriceMaurice May. 11 at 10:24 PM
$SMMT $EGG $SER
0 · Reply
CapitalMonk
CapitalMonk May. 11 at 8:41 PM
$SMMT Price: $18.66 (+3.21%) Trend: Bearish Market Bias (7D): Bullish Bias 📈 Expected Range: ±6.07% RSI: 25.2 | Momentum: Strong Downside Volume: -28.1% vs avg Volatility: 7.88% Support: $15.14 | Resistance: $29.23 Tools used: https://www.trade-ideas.com Code: INTERSTOCK25
0 · Reply
Dcvfin
Dcvfin May. 11 at 5:16 PM
$SMMT guess this guy is heading up Hoping for a little more time down in the 16-17 range but ok
0 · Reply
Latest News on SMMT
Summit Therapeutics Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

May 4, 2026, 9:23 AM EDT - 9 days ago

Summit Therapeutics Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Summit Therapeutics price target lowered to $23 from $30 at H.C. Wainwright

2026-05-04T10:22:41.000Z - 9 days ago

Summit Therapeutics price target lowered to $23 from $30 at H.C. Wainwright

Summit Therapeutics falls -23.7%

2026-05-01T16:04:50.000Z - 11 days ago

Summit Therapeutics falls -23.7%

Summit Therapeutics falls -27.4%

2026-05-01T14:55:38.000Z - 11 days ago

Summit Therapeutics falls -27.4%

Summit Therapeutics price target lowered to $16 from $17 at Piper Sandler

2026-05-01T11:33:37.000Z - 12 days ago

Summit Therapeutics price target lowered to $16 from $17 at Piper Sandler

Summit Therapeutics price target lowered to $31 from $32 at Clear Street

2026-04-30T23:55:23.000Z - 12 days ago

Summit Therapeutics price target lowered to $31 from $32 at Clear Street

Summit Therapeutics reports Q1 adjusted EPS (15c), consensus (21c)

2026-04-30T20:53:09.000Z - 12 days ago

Summit Therapeutics reports Q1 adjusted EPS (15c), consensus (21c)

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2026

Apr 30, 2026, 4:32 PM EDT - 12 days ago

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2026

Summit Therapeutics options imply 7.3% move in share price post-earnings

2026-04-30T19:29:07.000Z - 12 days ago

Summit Therapeutics options imply 7.3% move in share price post-earnings

Summit Therapeutics put volume heavy and directionally bearish

2026-04-23T14:55:17.000Z - 19 days ago

Summit Therapeutics put volume heavy and directionally bearish

Summit partner selection for ASCO plenary signals strong OS, says Leerink

2026-04-21T17:15:44.000Z - 21 days ago

Summit partner selection for ASCO plenary signals strong OS, says Leerink

BNTX

Summit partner selection for ASCO ‘likely a major positive,’ says Guggenheim

2026-04-21T16:09:04.000Z - 21 days ago

Summit partner selection for ASCO ‘likely a major positive,’ says Guggenheim

Biotech Alert: Searches spiking for these stocks today

2026-04-20T16:40:13.000Z - 22 days ago

Biotech Alert: Searches spiking for these stocks today

CGON

Biotech Alert: Searches spiking for these stocks today

2026-04-17T14:45:45.000Z - 25 days ago

Biotech Alert: Searches spiking for these stocks today

GUTS

Summit Therapeutics initiated with a Buy at Stifel

2026-04-07T20:23:11.000Z - 5 weeks ago

Summit Therapeutics initiated with a Buy at Stifel

Summit Therapeutics to present multiple ivonescimab data sets at ELCC 2026

2026-03-27T12:21:38.000Z - 6 weeks ago

Summit Therapeutics to present multiple ivonescimab data sets at ELCC 2026

Multiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 2026

Mar 27, 2026, 8:15 AM EDT - 6 weeks ago

Multiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 2026

Summit Therapeutics downgraded to Hold from Buy at Jefferies

2026-03-16T09:15:05.000Z - 2 months ago

Summit Therapeutics downgraded to Hold from Buy at Jefferies

Summit Therapeutics Transcript: The Citizens Life Sciences Conference 2026

Mar 11, 2026, 2:15 PM EDT - 2 months ago

Summit Therapeutics Transcript: The Citizens Life Sciences Conference 2026

Summit Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 2:30 PM EST - 2 months ago

Summit Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Summit Therapeutics to Present at Upcoming Investor Conferences

Feb 26, 2026, 6:45 PM EST - 2 months ago

Summit Therapeutics to Present at Upcoming Investor Conferences

Summit Therapeutics price target lowered to $30 from $40 at H.C. Wainwright

2026-02-24T12:01:45.000Z - 2 months ago

Summit Therapeutics price target lowered to $30 from $40 at H.C. Wainwright

Citi adds ‘upside 90-day catalyst watch’ on Summit Therapeutics

2026-02-24T10:50:36.000Z - 2 months ago

Citi adds ‘upside 90-day catalyst watch’ on Summit Therapeutics

Summit Therapeutics Earnings Call Transcript: Q4 2025

Feb 23, 2026, 4:30 PM EST - 2 months ago

Summit Therapeutics Earnings Call Transcript: Q4 2025

Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025

Feb 23, 2026, 4:05 PM EST - 2 months ago

Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025

Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results & Operational Progress Call on February 23, 2026

Feb 17, 2026, 5:05 PM EST - 3 months ago

Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results & Operational Progress Call on February 23, 2026

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 30, 2026, 4:30 PM EST - 3 months ago

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy

Jan 29, 2026, 7:30 AM EST - 3 months ago

Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy

Summit Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 12:45 PM EST - 4 months ago

Summit Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK's B7-H3 Antibody Drug Conjugate (ADC)

Jan 12, 2026, 6:15 AM EST - 4 months ago

Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK's B7-H3 Antibody Drug Conjugate (ADC)

GSK

Summit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC

Jan 12, 2026, 6:00 AM EST - 4 months ago

Summit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC

Summit Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 6, 2026, 7:30 AM EST - 4 months ago

Summit Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Summit Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 3, 2025, 2:10 PM EST - 5 months ago

Summit Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Summit Therapeutics Transcript: Citi Annual Global Healthcare Conference 2025

Dec 2, 2025, 10:30 AM EST - 5 months ago

Summit Therapeutics Transcript: Citi Annual Global Healthcare Conference 2025

Summit Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 18, 2025, 10:30 AM EST - 6 months ago

Summit Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Summit Therapeutics Transcript: UBS Global Healthcare Conference 2025

Nov 10, 2025, 3:30 PM EST - 6 months ago

Summit Therapeutics Transcript: UBS Global Healthcare Conference 2025

Ivonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in HARMONi-A Study Conducted by Akeso in China

Nov 7, 2025, 9:00 AM EST - 6 months ago

Ivonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in HARMONi-A Study Conducted by Akeso in China

Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025

Oct 31, 2025, 7:00 AM EDT - 6 months ago

Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025

Summit Therapeutics Raises $500 Million in Private Placement

Oct 22, 2025, 8:00 AM EDT - 7 months ago

Summit Therapeutics Raises $500 Million in Private Placement

Summit Therapeutics Earnings Call Transcript: Q3 2025

Oct 20, 2025, 8:00 AM EDT - 7 months ago

Summit Therapeutics Earnings Call Transcript: Q3 2025

Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2025

Oct 20, 2025, 6:45 AM EDT - 7 months ago

Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2025

Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China

Oct 19, 2025, 10:30 AM EDT - 7 months ago

Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China

Summit Therapeutics Announces Expansion of Ivonescimab Global Phase III Development Program with HARMONi-GI3 Study in 1L Colorectal Cancer

Oct 17, 2025, 7:00 AM EDT - 7 months ago

Summit Therapeutics Announces Expansion of Ivonescimab Global Phase III Development Program with HARMONi-GI3 Study in 1L Colorectal Cancer

Summit Therapeutics to Host ESMO Data Update & Third Quarter Earnings Call on October 20, 2025

Oct 15, 2025, 7:00 AM EDT - 7 months ago

Summit Therapeutics to Host ESMO Data Update & Third Quarter Earnings Call on October 20, 2025

HARMONi-6, Featuring Ivonescimab Combined with Chemotherapy vs. Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in China, to be Showcased in Presidential Symposium at ESMO 2025

Sep 24, 2025, 7:00 AM EDT - 8 months ago

HARMONi-6, Featuring Ivonescimab Combined with Chemotherapy vs. Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in China, to be Showcased in Presidential Symposium at ESMO 2025

Summit Therapeutics: Buy the Next Dip Amid Clinical Breakthrough Potential

Sep 17, 2025, 10:54 PM EDT - 8 months ago

Summit Therapeutics: Buy the Next Dip Amid Clinical Breakthrough Potential

Summit Therapeutics Inc. Investigated by the Portnoy Law Firm

Sep 16, 2025, 4:31 PM EDT - 8 months ago

Summit Therapeutics Inc. Investigated by the Portnoy Law Firm

CORRECTION -- Summit Therapeutics Inc. Investigated by the Portnoy Law Firm

Sep 10, 2025, 12:43 AM EDT - 8 months ago

CORRECTION -- Summit Therapeutics Inc. Investigated by the Portnoy Law Firm

Summit Therapeutics Transcript: Study Update

Sep 8, 2025, 8:00 AM EDT - 8 months ago

Summit Therapeutics Transcript: Study Update

Ivonescimab Plus Chemotherapy Demonstrates Consistent Global Benefit: HARMONi Data Update Shows OS HR=0.78, Nominal P=0.0332

Sep 7, 2025, 6:08 AM EDT - 8 months ago

Ivonescimab Plus Chemotherapy Demonstrates Consistent Global Benefit: HARMONi Data Update Shows OS HR=0.78, Nominal P=0.0332

Longer-Term Follow-Up of Western Patients Showed Improving, Favorable Trend in Overall Survival in Global Phase III HARMONi Clinical Trial for Ivonescimab Plus Chemotherapy in 2L+ EGFRm NSCLC

Sep 7, 2025, 3:30 AM EDT - 8 months ago

Longer-Term Follow-Up of Western Patients Showed Improving, Favorable Trend in Overall Survival in Global Phase III HARMONi Clinical Trial for Ivonescimab Plus Chemotherapy in 2L+ EGFRm NSCLC

Summit Therapeutics to Host Update Call at WCLC 2025 on September 8, 2025

Sep 3, 2025, 7:00 AM EDT - 9 months ago

Summit Therapeutics to Host Update Call at WCLC 2025 on September 8, 2025

Ivonescimab Data from Global Phase III HARMONi Study to be Showcased at Presidential Symposium at WCLC 2025

Aug 14, 2025, 7:00 AM EDT - 9 months ago

Ivonescimab Data from Global Phase III HARMONi Study to be Showcased at Presidential Symposium at WCLC 2025

Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2025

Aug 11, 2025, 5:03 PM EDT - 9 months ago

Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2025

Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors

Jun 30, 2025, 8:00 AM EDT - 11 months ago

Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors

RVMD

Summit Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

Jun 9, 2025, 1:20 PM EDT - 1 year ago

Summit Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

Summit Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

Jun 5, 2025, 8:00 AM EDT - 1 year ago

Summit Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

Is SMMT Stock A Buy After Its Recent Plunge?

Jun 2, 2025, 9:10 AM EDT - 1 year ago

Is SMMT Stock A Buy After Its Recent Plunge?

Summit Therapeutics Study Is a Win for China Biopharma Deals. Why the Stock Is Down.

May 30, 2025, 9:27 AM EDT - 1 year ago

Summit Therapeutics Study Is a Win for China Biopharma Deals. Why the Stock Is Down.

Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer after EGFR TKI Therapy in Global Study

May 30, 2025, 6:00 AM EDT - 1 year ago

Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer after EGFR TKI Therapy in Global Study

Final Trade: NVS, XLU and SMMT

May 1, 2025, 6:20 PM EDT - 1 year ago

Final Trade: NVS, XLU and SMMT

NVS XLU

Summit Therapeutics Earnings Call Transcript: Q1 2025

May 1, 2025, 4:30 PM EDT - 1 year ago

Summit Therapeutics Earnings Call Transcript: Q1 2025

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025

May 1, 2025, 4:09 PM EDT - 1 year ago

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025

Interim Overall Survival Analysis Requested from Chinese Health Authorities Shows a Clinically Meaningful, Positive Trend Favoring Ivonescimab Compared to Pembrolizumab in PD-L1 Positive Advanced NSCLC from HARMONi-2 Study Conducted by Akeso in China

Apr 25, 2025, 2:50 PM EDT - 1 year ago

Interim Overall Survival Analysis Requested from Chinese Health Authorities Shows a Clinically Meaningful, Positive Trend Favoring Ivonescimab Compared to Pembrolizumab in PD-L1 Positive Advanced NSCLC from HARMONi-2 Study Conducted by Akeso in China

Summit Therapeutics to Host First Quarter 2025 Financial Results & Operational Progress Call on May 1, 2025

Apr 24, 2025, 4:15 PM EDT - 1 year ago

Summit Therapeutics to Host First Quarter 2025 Financial Results & Operational Progress Call on May 1, 2025

Ivonescimab in Combination with Chemotherapy Achieves Statistically Significant Superiority in PFS vs. Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in HARMONi-6 Study Conducted by Akeso in China

Apr 23, 2025, 6:15 AM EDT - 1 year ago

Ivonescimab in Combination with Chemotherapy Achieves Statistically Significant Superiority in PFS vs. Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in HARMONi-6 Study Conducted by Akeso in China

Robert LaCaze, Innovative Growth-Driver in Oncology, Joins Summit Therapeutics as Chief Commercial Officer

Mar 17, 2025, 4:24 PM EDT - 1 year ago

Robert LaCaze, Innovative Growth-Driver in Oncology, Joins Summit Therapeutics as Chief Commercial Officer

Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCs

Feb 24, 2025, 8:13 PM EST - 1 year ago

Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCs

PFE

Summit Therapeutics Earnings Call Transcript: Q4 2024

Feb 24, 2025, 9:00 AM EST - 1 year ago

Summit Therapeutics Earnings Call Transcript: Q4 2024

Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Twelve Months Ended December 31, 2024

Feb 24, 2025, 6:05 AM EST - 1 year ago

Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Twelve Months Ended December 31, 2024

Summit Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Ivonescimab in Combination with Pfizer Antibody Drug Conjugates (ADCs)

Feb 24, 2025, 6:00 AM EST - 1 year ago

Summit Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Ivonescimab in Combination with Pfizer Antibody Drug Conjugates (ADCs)

PFE

Summit Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results & Operational Progress Call on February 24, 2025

Feb 18, 2025, 9:00 AM EST - 1 year ago

Summit Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results & Operational Progress Call on February 24, 2025

Summit Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 13, 2025, 6:00 PM EST - 1 year ago

Summit Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Summit Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 7, 2025, 7:00 AM EST - 1 year ago

Summit Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Summit Therapeutics Transcript: Citi's 2024 Global Healthcare Conference

Dec 4, 2024, 8:45 AM EST - 1 year ago

Summit Therapeutics Transcript: Citi's 2024 Global Healthcare Conference

Summit Therapeutics Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference

Dec 3, 2024, 8:45 AM EST - 1 year ago

Summit Therapeutics Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference

Summit Therapeutics Earnings Call Transcript: Q3 2024

Oct 30, 2024, 9:00 AM EDT - 1 year ago

Summit Therapeutics Earnings Call Transcript: Q3 2024

Summit Therapeutics Reports Operational Progress and Financial Results for the Third Quarter and Nine Months Ended September 30, 2024

Oct 30, 2024, 7:00 AM EDT - 1 year ago

Summit Therapeutics Reports Operational Progress and Financial Results for the Third Quarter and Nine Months Ended September 30, 2024

Summit Therapeutics to Host Third Quarter 2024 Financial Results & Operational Progress Call on October 30, 2024

Oct 23, 2024, 4:15 PM EDT - 1 year ago

Summit Therapeutics to Host Third Quarter 2024 Financial Results & Operational Progress Call on October 30, 2024

LoveRetailFroth
LoveRetailFroth May. 13 at 1:19 PM
$REPL Good Morning ☕️ My 💎 s $AMLX $SMMT $RXRX $SANA
0 · Reply
Teluride
Teluride May. 12 at 11:21 PM
$SMMT
3 · Reply
TruthBroker2
TruthBroker2 May. 12 at 5:32 PM
$SMMT $PLSE They Know.
0 · Reply
TruthBroker2
TruthBroker2 May. 12 at 2:41 PM
$SMMT 18.88
0 · Reply
SmokeWagon
SmokeWagon May. 12 at 2:15 PM
$SMMT !!!
0 · Reply
LeisureSuitLarry
LeisureSuitLarry May. 12 at 1:51 PM
$SMMT
0 · Reply
LoveRetailFroth
LoveRetailFroth May. 12 at 1:48 PM
$REPL Good Morning 💎s $AMLX $SMMT $SANA $RXRX
0 · Reply
MauriceMauriceMaurice
MauriceMauriceMaurice May. 11 at 10:24 PM
$SMMT $EGG $SER
0 · Reply
CapitalMonk
CapitalMonk May. 11 at 8:41 PM
$SMMT Price: $18.66 (+3.21%) Trend: Bearish Market Bias (7D): Bullish Bias 📈 Expected Range: ±6.07% RSI: 25.2 | Momentum: Strong Downside Volume: -28.1% vs avg Volatility: 7.88% Support: $15.14 | Resistance: $29.23 Tools used: https://www.trade-ideas.com Code: INTERSTOCK25
0 · Reply
Dcvfin
Dcvfin May. 11 at 5:16 PM
$SMMT guess this guy is heading up Hoping for a little more time down in the 16-17 range but ok
0 · Reply
TruthBroker2
TruthBroker2 May. 11 at 4:35 PM
$SMMT
0 · Reply
EB2224
EB2224 May. 11 at 2:20 PM
$SMMT
0 · Reply
LeisureSuitLarry
LeisureSuitLarry May. 11 at 2:18 PM
$SMMT
0 · Reply
db59
db59 May. 11 at 1:55 PM
$SMMT 14 trading days until ASCO plenary session on May 31. It’s possible that another run-up to mid- to high 20’s and even low 30’s might be coming before then. NB: The iDMC-only interim results for HARMONi-3 preserves nearly all the p-value for the H2 PFS final analysis later this year - that’s very good.
0 · Reply
SuperGreenToday
SuperGreenToday May. 11 at 1:47 PM
$SMMT Share Price: $18.79 Contract Selected: Jun 05, 2026 $20 Calls Buy Zone: $1.91 – $2.36 Target Zone: $3.58 – $4.37 Potential Upside: 77% ROI Time to Expiration: 24 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
BooEmmy
BooEmmy May. 11 at 1:41 PM
$SMMT
0 · Reply
SmokeWagon
SmokeWagon May. 11 at 1:35 PM
$SMMT !!! 😏
0 · Reply
LoveRetailFroth
LoveRetailFroth May. 11 at 1:29 PM
$SMMT Good Morning 💎 s ☕️ . $AMLX $SANA $RXRX $REPL
0 · Reply
Reneejordan001
Reneejordan001 May. 10 at 1:59 PM
$SMMT Here is the image from their LinkedIn page. I presume you are a SHORTIE. 👇🥴
0 · Reply
Dcvcool
Dcvcool May. 10 at 2:24 AM
$SMMT not sure if this one is dipping down this coming week or heading back up but I’m leaning towards dipping down some more
1 · Reply
CyberHawk
CyberHawk May. 10 at 2:19 AM
$SMMT n late January 2026, the FDA accepted the Biologics License Application (BLA) for ivonescimab in combination with chemotherapy for patients with EGFR-mutated NSCLC. This remains the primary long-term value driver
0 · Reply
SmokeWagon
SmokeWagon May. 9 at 2:56 PM
$SMMT !!!
0 · Reply